Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
Two abstracts accepted for oral presentation at the 13th London International Cough Symposium
Trevi Representatives: Jennifer Good, President and CEO, and
The Thirteenth London International Cough Symposium
Abstract 1: Sample Size Reestimation in an Ongoing Dose-ranging Study of Nalbuphine Extended-release For Cough in Idiopathic Pulmonary Fibrosis (CORAL)
Abstract 2: Efficacy And Safety of Nalbuphine Extended-release Tablets for the Treatment of Refractory Chronic Cough: A Phase 2 Trial in Progress (RIVER)
Symposium Focus: The Thirteenth London International Cough Symposium brings together clinicians, scientists, and researchers in the field of cough from across the world. The purpose of this symposium is to share, review and discuss emerging ideas, novel approaches, and clinical research advancements in the management of chronic cough.
Registration details
Oppenheimer's Biotech in the Berkshires
Trevi Representative:
Stifel 2024 Biotech
Trevi Representatives:
About Trevi Therapeutics, Inc.
The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal relief to patients. RCC affects up to 10% of the adult population, and Haduvio's expansion into RCC has the potential to reach patients suffering from moderate to severe chronic cough. There are also no approved therapies for RCC in the US.
Parenteral nalbuphine is not scheduled by the
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
914-815-1465
rscampoli@marketcompr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-investor-and-healthcare-events-302187587.html
SOURCE